Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
Recruiting · NCT07629596 · Registry updated 2026-06-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA) | Hemic and Lymphatic Diseases, Skin and Connective Tissue Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, connective tissue disorder, hematologic disorder, hemolytic anemia, immune system disorder, systemic lupus erythematosus | Recruiting | Early phase 1 | 2026-06-05 | NCT07629596 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Boji Medical Technology Co., Ltd. | 3 |
| Circunited BioPharma (Shenzhen) Co., Ltd. | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing GoBroad Boren Hospital | Beijing | China | 2 |